Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqCM - Delayed Quote USD

Entero Therapeutics, Inc. (ENTO)

Compare
0.4101
-0.0700
(-14.58%)
At close: April 1 at 4:00:00 PM EDT
0.4420
+0.03
+(7.78%)
After hours: April 1 at 6:16:19 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ENTO

Recent News: ENTO

View More
Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC

Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC
Newsfile 8 days ago
Entero Therapeutics Appoints Richard Paolone as CEO

Entero Therapeutics Appoints Richard Paolone as CEO
GlobeNewswire last month
Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members

Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members
GlobeNewswire last month
Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum

Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum
GlobeNewswire 4 months ago
Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company
GlobeNewswire 4 months ago
Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings

Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings
GlobeNewswire 6 months ago
Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q
GlobeNewswire 7 months ago
Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program
GlobeNewswire 7 months ago
Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds

Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds
GlobeNewswire 8 months ago
Entero Therapeutics Announces Abstract on Celiac Disease Research Accepted for Presentation at the 20th International Celiac Disease Symposium

Entero Therapeutics Announces Abstract on Celiac Disease Research Accepted for Presentation at the 20th International Celiac Disease Symposium
GlobeNewswire 8 months ago
Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease

Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease
GlobeNewswire 8 months ago
View More

Related Tickers

TNFA TNF Pharmaceuticals, Inc.
0.4419
+26.26%
 
PASG Passage Bio, Inc.
0.3860
+9.32%
 
ERNA Ernexa Therapeutics Inc.
0.1849
+3.88%
 
PBM Psyence Biomedical Ltd.
0.5921
-1.32%
 
PALI Palisade Bio, Inc.
0.6698
-1.62%
 
OGEN Oragenics, Inc.
0.2123
+1.10%
 
VINC Vincerx Pharma, Inc.
0.5750
+8.61%
 
SPRC SciSparc Ltd.
0.2809
-5.74%
 
SXTP 60 Degrees Pharmaceuticals, Inc.
1.8900
+5.00%
 
CMMB Chemomab Therapeutics Ltd.
1.0400
-4.59%